Trial Profile
A French large-scale, nationwide propensity-matched cohort study to compare of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin k antagonists
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Dec 2015
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary) ; Rivaroxaban (Primary)
- Indications Arterial thrombosis; Ischaemia; Thromboembolism
- Focus Therapeutic Use
- 28 Dec 2015 New trial record